Cutaneous complications of hormonal replacement therapy

Clinics in Dermatology

Volumn 15, Issue 1, 1997, Pages 147-154

  Mor, Ze'ev ^a   Caspi, Eliahu ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN;

FEMALE; HORMONE SUBSTITUTION; HUMAN; IMMUNOPATHOGENESIS; MALIGNANT MENINGIOMA; MENOPAUSAL SYNDROME; PORPHYRIA CUTANEA TARDA; PRIORITY JOURNAL; REVIEW; SKIN DISEASE; SKIN PIGMENTATION; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0031081443     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0738-081X(96)00117-4     Document Type: Article

References (88)

1. 1. Wren GW, Eden JA. Hormone Replacement Therapy. A review - Part I. The Female Patient 1994;4:5-16.
2. 2. Barrett-Connor E. Epidemiology and the menopause: A global overview. Int J Fertil Menopausal Stud 1993;38 (Suppl 1):6-14.
3. 3. Zichella L. Clinical management of the menopausal women. Int J Fertil Menopausal Stud. 1993;38(Suppl 1): 15-22.
4. 4. Gordon T, Kannel WB, Hjortland MC, et al. Menopause and coronary heart disease: The framingham study. Ann Intern Med 1978;89:157-61.
5. 5. Riggs BL. Melton LJ III. Medical progress: Involutional osteoporosis. N Engl J Med 1986;314:1676-84.
6. 6. Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women. JAMA 1991;265:1861-7.
7. 7. Ettinger B, Genant HK, Cann CE. Long term estrogen replacement therapy prevents bone loss and fractures. Ann Intern Med 1985;102:319-24.
8. 8. Ciocca DR, Vargas Roig LM. Estrogen receptors in human nontarget tissues: Biological and clinical implications. Endocrine Reviews 1995;16:35-62.
9. 9. Fraser D, Padwick ML, Whitehead M, et al. Presence of an Oestradiol receptor-related protein in the skin: Changes during the normal menstrual cycle. Br J Obstet Gynecol 1991;98:1277-82.
10. 10. Brincat M, Studd J. Skin and the menopause. In: Studd JWW, Whitlehead MI, editors. The Menopause. ? Blackwell Scientific Publications 1988;85-101.
11. 11. Brincat M, Versi E, Moniz CF, et al. Skin collagen changes in postmenopausal women receiving different regimes of estrogen therapy. Obstet Gynecol 1987;70:123-7.
12. 12. Castelo-Branco C, Duran M, Gonzalez-Merlo J. Skin collagen changes related to hormone replacement therapy. Maturitas 1992;15:113-9.
13. 13. Savvas M, Bishop J, Laurent G, et al. Type III collagen content in the skin of postmenopausal women receiving oestradiol and testosterone implants. Br J Obstet Gynecol 1993;100:154-6.
14. 14. Varila E, Rantala I, Oikarinen A, et al. The effect of topical oestradiol on skin collagen of postmenopausal women. Br J Obstet Gynecol 1995;102:985-9.
15. 15. Bolognia JL, Braverman IM, Rousseau ME, et al. Skin changes in menopause. Maturitas 1989;11:295-304.
16. 16. Punnonen R, Vaajalahti P, Tiesala K. Local oestriol treatment improves the structure of elastic fibers in the skin of postmenopausal women. Ann Chirur Gynaecol 1987;76(S 202):39-41.
17. 17. Pierard GE, Letawe C, Dowlati A, et al. Effect of hormone replacement therapy for menopause on the mechanical properties of skin. J Ann Geriatric Soc 1995;43:662-5.
18. 18. Pierard-Franchimont C, Letawe C, Goffin V, et al. Skin water holding capacity and transdermal estrogen therapy for menopause: a pilot study. Maturitas 1995;22:151-4.
19. 19. Wei Q, Matanoski GM, Farmer ER et al. DNA repair related to multiple skin cancers and drug use. Cancer Research 1994;54:437-40.
20. 20. Errickson CV, Matus NR. Skin disorders of pregnancy. Am Family Physician 1994;49:605-12.
21. 21. Brenner S, Politi Y. Dermatologic diseases and problems of women throughout the life cycle. Int J Dermatol 1995; 34:369-79.
22. 22. Verthelyi D, Ansar Ahmed S. 17-β-estradiol but not 5-α-dihydrotestosterone augments antibodies to double stranded deoxyribonucleic acid in nonautoimmune C57BL/6J mice. Endocrinology 1994;135:2615-22.
23. 23. Beeson PB. Age and sex associations of 40 autoimmune diseases. Am J Med 1994;96:457-62.
24. 24. Cutolo M, Sulli A, Seriolo B, et al. Estrogens, the immune response and autoimmunity. Clin Experiment Rheumatol 1995;13:217-26.
25. 25. Van Vollenhoven RF, McGuire JL. Estrogen, progesterone and testosterone: Can they be used to treat autoimmune diseases? Cleve Clin J Med 1994;61:276-84.
26. 26. Ansar Ahmed S, Verthelyi D. Antibodies to dardiolipin in normal C57BL/6J mice. Induction by estrogen but not dihydrotestosterone. J Autoimmune 1993;6:265-79.
27. 27. Blank M, Mendelovic S, Fricke H, et al. Sex hormone involvement in the induction of experimental systemic lupus erythematosus by a pathogenic anti-DNA idiotype in naive mice. J Rheumatol 1990;17:311-7.
28. 28. Sthoeger ZM, Bentwich Z, Zinger H, et al. The beneficial effect of the estrogen antagonist, Tamoxifen, on experimental systemic lupus erythematosus. J Rheumatol 1994; 21:2231-8.
29. 29. Ben Chetrit A, Ben Chetrit E. Systemic lupus erythematosus induced by ovulation induction treatment. Arthritis and Rheumatism 1994;37:1614-7.
30. 30. Boumpas DT, Fessler BJ, Austin III HA, et al. Systemic lupus erythematosus. Emerging concepts. Part 2. Ann Intern Med 1995;123:42-53.
31. 31. Sanchez-Guerrero J, Liang MH, Karlson EW, et al. Post-menopausal estrogen therapy and the risk for developing systemic lupus erythematosus. Ann Intern Med 1995;122: 430-3.
32. 32. Arden NK, Lloyd ME, Spector TD, et al. Safety of hormone replacement therapy (HRT) in systemic lupus erythematosus (SLE). Lupus 1994;3:11-3.
33. 33. Yell JA, Burge SM. The effect of hormonal changes on cutaneous disease in lupus erythematosus. J Rheumatol 1994;3:11-3.
34. 34. Shelley WB, Preucel RW, Spoont SS. Autoimmune progesterone dermatitis. JAMA 1964;190:35-8.
35. 35. Stephens CJM, McFadden JP, Black MM, et al. Autoimmune progesterone dermatitis: Absence of contact sensitivity to glucocorticoids, oestrogen and 17-α-OH-Progesterone. Contact Dermatitis 1994;31:108-10.
36. 36. Shelley WB, Shelley ED, Talamin NY, et al. Estrogen dermatitis. J Am Acad Dermatol 1995;32:25-31.
37. 37. Mayou SC, Charles-Holmes R, Kenney A, et al. A premenstrual eruption treated with bilateral oophorectomy and hysterectomy. Clin Exp Dermatol 1988;13:114-6.
38. 38. Grossman ME, Bickers DR, Poh-Fitzpatrick MB, et al. Porphyria cutanea tarda. Am J Med 1979;67:277-86.
39. 39. Koszo F, Morvay M, Dobozy A, et al. Erythrocyte uroporphyrinogen decarbxoxylase activity in 80 unrelated patients with porphyria cutanea tarda. Br J Dermatol 1992; 126:446-9.
40. 40. Stein KM, Raque CJ, Zeigerman JH, et al. Porphyria cutanea tarda induced by natural estrogens. Obstet Gynecol 1971;38:755-60.
41. 41. Olumide YM. Photodermatoses in Lagos. Int J Dermatol 1987;26:295-9.
42. 42. Urbanek RW, Cohen DJ. Porhphyria cutanea tarda: pregnancy versus estrogen effect. J Am Acad Dermatol 1994; 31:390-2.
43. 43. Jimbow K, Quevedo C, Fitzpatrick TB, et al. Biology of melanocytes. In: Fitzpatrick TB, et al. editors. Dermatology in general medicine. Vol. 1 4th ed. New York: McGraw-Hill (International Edition), 1993;261-88.
44. 44. Grimes PE. Melasma. Etiologic and therapeutic consideration. Arch Dermatol 1995;131:1453-7.
45. 45. Claudy AL. Perrot JL. Hyperpigmentation induced by UVB at the application site of estradiol. Dermatologica 1990;181:154-5.
46. 46. Ferno M, Borg A, Ingvar C, et al. Estrogen receptor and binding site for extramustine in metastatic malignant melanoma. Anticancer Research 1987;7:741-4.
47. 47. Ferno M, Borg A, Ericksen C, et al. Estrogen and progesterone receptors in melanoma metastases with special reference to analytical methods and prognosis. Anticancer Research 1984;4:179-82.
48. 48. Creagan ET, Ingle JN, Woods JE, et al. Estrogen receptors in patients with malignant melanoma. Cancer 1980;46: 1785-6.
49. 49. Flowers JL, Seigler HF, McCarty KS, et al. Absence of estrogen receptors in human melanoma as evaluated by a monoclonal anti-estrogen receptor antibody. Arch Dermatol 1987;123:764-5.
50. 50. Cohen C, DeRose PB, Campbell WG, et al. Estrogen receptor status in malignant melanoma. Am J Dermatopathol 1990;12:562-4.
51. 51. Walker MJ, Beattie CW, Patel MK, et al. Estrogen receptor in malignant melanoma. J Clin Oncol 1987;5:1256-61.
52. 52. Schleicher IL, Hitselberger MH, Beattie CW. Inhibition of hamster melanoma growth by estrogen. Cancer Research 1987;47:453-9.
53. 53. Lecavalier MA, From L, Gaid N. Absence of estrogen receptors in dysplastic nevi and malignant melanoma. J Am Acad Dermatol 1990;23:242-6.
54. 54. Beattie CW, Ronan SG, Amoss MS. Estrogens influence the natural history of Sinclair Swine cutaneous melanoma. Cancer Research 1991;51:2025-8.
55. 55. Gallagher RP, Elwood JM, Hill GB, et al. Reproductive factors, oral contraceptives and risk of malignant melanoma. Western Canada Melanoma Study. Br J Cancer 1985;52:901-7.
56. 56. Franceschi S, Baron AE, La Vecchia C. The influence of female hormones on malignant melanoma. Tumori 1990; 76:439-49.
57. 57. Lederman CS, Lew RA, Koh HK, et al. Influence of estrogen administration in tumor characteristics and survival in women with cutaneous melanoma. J Nat Cancer Inst 1985;74:981-5.
58. 58. Sawaya ME, Garland LD, Rothe MJ, et al. Oestrogen and progesterone receptors in lentigo maligna. Br J Dermatol 1988;118:69-71.
59. 59. Ellis DL, Nanney LB, King LE. Increased epidermal growth factor receptors in seborrheic keratoses and acrochordons of patients with the dysplastic nevus syndrome. J Am Acad Dermatol 1990;23:1070-7.
60. 60. Branchi L, Lubrano C, Carrozzo AM, et al. Pachydermoperiostosis: Study of epidermal growth factor and steroid receptors. Br J Dermatol 1995;132:128-33.
61. 61. Sickel JZ. Cutaneous ciliated cyst of the scalp. Am J Dermatol 1994;16:76-9.
62. 62. Hogan DJ, Maibach HI. Adverse dermatologic reactions to transdermal drug delivery systems. J Am Acad Dermatol 1990;22:811-4.
63. 63. Pedersen OD, Jensen HK. Long term treatment with transcoutaenous estradiol and oral medroxyprogesterone acetate. Acta Obstet Gynecol Scand 1992;71:593-8.
64. 64. Cheang A, Sitruk-Ware R, Utian WH. A risk benefit appraisal of transdermal estradiol therapy. Drug Saf 1993;9: 365-79.
65. 65. Utian WH. Transdermal estradiol overall safety profile. Am J Obstet Gynecol 1987;156:1335-8.
66. 66. Lufkin EG, Ory SJ. Relative value of transdermal and oral estrogen therapy in various clinical situations. Mayo Clin Proc 1994;69:131-5.
67. 67. Frenkel Y, Kopernik G, Lazer S, et al. Acceptability and skin reactions to transdermal estrogen replacement therapy in relation to climate. Maturitas 1994;20:31-6.
68. 68. Baker VL. Alternatives to oral estrogen replacement. Obstet Gynecol Clin North Am 1994;21:271-97.
69. 69. Balfour JA, McTavish D. Transdermal estradiol. Drugs and Aging 1992;2:487-507.
70. 70. Youngkin EQ. Estrogen replacement therapy and the estraderm transdermal system. Nurse Pract 1990;15:19-26.
71. 71. McCarthy T, Dramusic V, Ratnam S. Use of two types of estradiol-releasing skin patches for menopausal patients in a tropical climate. Am J Obstet Gynecol 1992;166:2005-10.
72. 72. Erkkola R, Holma P, Jarvi T, et al. Transdermal oestrogen replacement therapy in a Finnish population. Maturitas 1991;13:275-81.
73. 73. The Transdermal HRT Investigators Group. A randomized study to compare the effectiveness, tolerability, and acceptability of two different transdermal estradiol replacement therapies. Int J Fertil 1993;38:5-11.
74. 74. Corson LC. Clinical experience with Systen, a new transdermal form of hormone replacement therapy. Int J Fertil 1993;38(Suppl 1):36-44.
75. 75. Van Leusden HAIM, Albertyn G, Verlaine C, et al. A comparative multicenter study of two transdermal estradiol replacement therapies in the treatment of postmenopausal symptoms. In J Fertil 1993;38:210-8.
76. 76. Carmichael AJ, Foulds IS. Allergic contact dermatitis from oestradiol in oestrogen patches. Contact Dermatitis 1992; 26:194-5.
77. 77. Pecquet C, Pradalier A, Dry J. Allergic contact dermatitis from ethanol in a transdermal estradiol patch. Contact Dermatitis 1992;27:275-6.
78. 78. Davis GF, Winter L. Cumulative irritation study of placebo transdermal estrogen patches. Curr Therap Res 1987; 42:712-9.
79. 79. McCarthy TG, Dramusic V, Ratnam S, et al. Use of 50 mcg Estraderm patches in a humid tropical climate. In: Proceedings of the 5th International Congress on the Menopause. Camforth: Parthenon Press, 1987;122.
80. 80. Sentrakul P, Chompootaweep S, Sintupak S. et al. Adverse skin reactions to transdermal oestradiol in tropical climate. A comparative study of skin tolerance after using oestradiol patch and gel in Thai postmenopausal women. Maturitas 1991;13:151-4.
81. 81. O'Neill S, Kirkegard Y. An Australian experience of transdermal oestradiol patches in a subtropical climate. Aust NZ J Obstet Gynecol 1993;33:327-9.
82. 82. Fraser D, Whitehead M, Schenkel L, et al. Does low-dose, transdermal norethisterone acetate reliable cause endometrial transformation in postmenopausal estrogen users? Maturitas 1993;16:22-30.
83. 83. Studd JWW, McCarthy K, Zamblera D, et al. Efficacy and tolerance of Menorest® compared to Premarin® in the treatment of postmenopausal women. A randomized, multicenter, double-blind, double dummy study. Maturitas 1995;22:105-14.
84. 84. Gordon SF, Thompson KA, Ruoff GE, et al. Efficacy and safety of a seven-day transdermal estradiol drug-delivery system: Comparison with conjugated estrogens and placebo. Int J Fertil 1995;40:126-34.
85. 85. Sentrakul P. Skin tolerance with cutaneous administration. In: N. Dusitsin, M. Notelovitz, editors.Physiological hormone replacement therapy. Camforth: Parthenon Publishing, 1991;61-4.
86. 86. Hoist J, Hofer PA, Cajander S, et al. Percutaneous estrogen therapy - a semi quantitative histologic study of the abdominal skin. Acta Obstet Gynecol Scand 1982;61:515-6.
87. 87. Stanczyk FZ, Shoupe D, Nunez V, et al: A randomized comparison of nonoral estradiol delivery in postmenopausal women. Am J Obstet Gynecol 1988;159:1540-6.
88. 88. Schmidt JB, Binder M, Macheiner W, et al. Treatment of skin ageing symptoms in perimenopausal females with estrogen compounds. A pilot study. Maturitas 1994;20:25-30.